biostudies-literatureDai LNingbo Health Branding Subject Fund19711https://www.ebi.ac.uk/biostudies/studies/S-EPMC8492645biostudies-literatureUnknown11(1)Immune checkpoint inhibitor therapy has shown promising results in patients with unresectable hepatocellular carcinoma. This study aimed to evaluate the effectiveness and safety of sintilimab, a programmed cell death protein-1 (PD-1) blockade, combined with sorafenib and transhepatic arterial chemotherapy and embolization in this patient population, compared with sintilimab monotherapy and sintilimab-sorafenib duotherapy. This was a 22 months single center retrospective cohort study in China. 80 patients with unresectable hepatocellular carcinoma were included, with diagnosis confirmed by either histologic, cytologic or diagnostic imaging analysis. The patients were divided into three groups based on therapeutic regimen: sintilimab monotherapy (sintilimab group, n = 22), sintilimab-sorafenScientific reportsTherapeutic effectiveness and safety of sintilimab-dominated triple therapy in unresectable hepatocellular carcinoma.PMC8492645PPXK2018-03Liu YDai LMao SLu CMugaanyi JCai XfalseTherapeutic effectiveness and safety of sintilimab-dominated triple therapy in unresectable hepatocellular carcinoma.Immune checkpoint inhibitor therapy has shown promising results in patients with unresectable hepatocellular carcinoma. This study aimed to evaluate the effectiveness and safety of sintilimab, a programmed cell death protein-1 (PD-1) blockade, combined with sorafenib and transhepatic arterial chemotherapy and embolization in this patient population, compared with sintilimab monotherapy and sintilimab-sorafenib duotherapy. This was a 22 months single center retrospective cohort study in China. 80 patients with unresectable hepatocellular carcinoma were included, with diagnosis confirmed by either histologic, cytologic or diagnostic imaging analysis. The patients were divided into three groups based on therapeutic regimen: sintilimab monotherapy (sintilimab group, n = 22), sintilimab-sorafen2021-01-01T00:00:00Z2021 Oct2025-04-22T11:32:26.444Z2022-02-11T11:58:09.316ZS-EPMC84926453461119510.1038/s41598-021-98937-2